A phase II study of alanosine in advanced large bowel carcinoma

Am J Clin Oncol. 1983 Apr;6(2):191-3. doi: 10.1097/00000421-198304000-00009.

Abstract

Thirty patients with advanced metastatic colorectal adenocarcinoma were treated with alanosine at a dose of 160 mg/m2 daily for 5 days every 4 weeks. Sixteen patients had received no prior chemotherapy and 14 had been previously treated with one or more cytotoxic agents. No patient met the criteria for a complete or partial response. The major toxicity was stomatitis.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adult
  • Aged
  • Alanine / adverse effects
  • Alanine / analogs & derivatives*
  • Alanine / therapeutic use
  • Antibiotics, Antineoplastic / adverse effects
  • Antibiotics, Antineoplastic / therapeutic use*
  • Colonic Neoplasms / drug therapy*
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nausea / chemically induced
  • Rectal Neoplasms / drug therapy*
  • Stomatitis / chemically induced

Substances

  • Antibiotics, Antineoplastic
  • alanosine
  • Alanine